Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape project

Introduction In a well-defined NSCLC cohort of the ETOP Lungscape program, we explored the epidemiology of IHC MET overexpression and amplification, their inter-correlation, and their association to outcome. Methods Resected NSCLC were assessed for MET gene copy number (GCN) and expression using sil...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bubendorf, Lukas (VerfasserIn) , Warth, Arne (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 22 July 2017
In: Lung cancer
Year: 2017, Jahrgang: 111, Pages: 143-149
ISSN:1872-8332
DOI:10.1016/j.lungcan.2017.07.021
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1016/j.lungcan.2017.07.021
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0169500217304002
Volltext
Verfasserangaben:Lukas Bubendorf, Urania Dafni, Martin Schöbel, Stephen P. Finn, Verena Tischler, Aleksandra Sejda, Antonio Marchetti, Erik Thunnissen, Eric K. Verbeken, Arne Warth, Irene Sansano, Richard Cheney, Ernst Jan M. Speel, Daisuke Nonaka, Kim Monkhorst, Henrik Hager, Miguel Martorell, Spasenija Savic, Keith M. Kerr, Qiang Tan, Zoi Tsourti, Thomas R. Geiger, Roswitha Kammler, Katja Schulze, Ashis Das-Gupta, David Shames, Solange Peters, Rolf A. Stahel

MARC

LEADER 00000caa a2200000 c 4500
001 1580646743
003 DE-627
005 20220815001351.0
007 cr uuu---uuuuu
008 180904s2017 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.lungcan.2017.07.021  |2 doi 
035 |a (DE-627)1580646743 
035 |a (DE-576)510646743 
035 |a (DE-599)BSZ510646743 
035 |a (OCoLC)1341017882 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Bubendorf, Lukas  |d 1964-  |e VerfasserIn  |0 (DE-588)1075775744  |0 (DE-627)833840029  |0 (DE-576)444656812  |4 aut 
245 1 0 |a Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC  |b results from the European Thoracic Oncology Platform (ETOP) Lungscape project  |c Lukas Bubendorf, Urania Dafni, Martin Schöbel, Stephen P. Finn, Verena Tischler, Aleksandra Sejda, Antonio Marchetti, Erik Thunnissen, Eric K. Verbeken, Arne Warth, Irene Sansano, Richard Cheney, Ernst Jan M. Speel, Daisuke Nonaka, Kim Monkhorst, Henrik Hager, Miguel Martorell, Spasenija Savic, Keith M. Kerr, Qiang Tan, Zoi Tsourti, Thomas R. Geiger, Roswitha Kammler, Katja Schulze, Ashis Das-Gupta, David Shames, Solange Peters, Rolf A. Stahel 
264 1 |c 22 July 2017 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 04.09.2018 
520 |a Introduction In a well-defined NSCLC cohort of the ETOP Lungscape program, we explored the epidemiology of IHC MET overexpression and amplification, their inter-correlation, and their association to outcome. Methods Resected NSCLC were assessed for MET gene copy number (GCN) and expression using silver in-situ hybridization (SISH) and immunohistochemistry (IHC) on TMAs in a multicenter setting. MET amplification was defined as MET/centromere ratio≥2 (with average MET GCN≥4), high MET GCN as CGN≥5 and MET IHC+ as ≥2+ intensity in ≥50% of tumor cells. A total of 182 MET IHC+ and EGFR/KRAS WT tumors were analyzed for METex14 skipping mutation. Results MET IHC+ was found in 23.8% of 2432 patients, significantly associated with female gender, small tumor size, and adenocarcinoma histology. We observed a high inter-laboratory variability in IHC and SISH analysis. MET amplification prevailed in 4.6% and MET GCN≥5 in 4.1% of 1572 patients. MET amplification and MET GCN≥5 were not significantly associated with any tumor characteristics or stage. Both were significantly associated with IHC MET positivity (p<0.001). METex14 skipping mutation prevailed in 5 of 182 (2.7%) MET IHC+ WT EGFR/KRAS NSCLC, 4 of which within the 88 adenocarcinomas (4.5%). No association of IHC MET overexpression, SISH MET amplification or high MET GCN was found with OS, RFS or TTR. Conclusion MET overexpression is found in 23.8% of surgically resected NSCLC. MET amplification prevails in 4.6% and is associated with MET overexpression. Both have no influence on prognosis. The large inter-laboratory variability in IHC highlights the challenge of MET IHC analysis in routine practice. 
650 4 |a exon14 mutation 
650 4 |a IHC MET overexpression 
650 4 |a Non-small cell lung carcinoma 
650 4 |a SISH amplification 
700 1 |a Warth, Arne  |d 1979-  |e VerfasserIn  |0 (DE-588)132646145  |0 (DE-627)524716927  |0 (DE-576)260019755  |4 aut 
773 0 8 |i Enthalten in  |t Lung cancer  |d Amsterdam [u.a.] : Elsevier, 1985  |g 111(2017), Seite 143-149  |h Online-Ressource  |w (DE-627)320649733  |w (DE-600)2025812-4  |w (DE-576)264627539  |x 1872-8332  |7 nnas  |a Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC results from the European Thoracic Oncology Platform (ETOP) Lungscape project 
773 1 8 |g volume:111  |g year:2017  |g pages:143-149  |g extent:7  |a Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC results from the European Thoracic Oncology Platform (ETOP) Lungscape project 
856 4 0 |u http://dx.doi.org/10.1016/j.lungcan.2017.07.021  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S0169500217304002  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180904 
993 |a Article 
994 |a 2017 
998 |g 132646145  |a Warth, Arne  |m 132646145:Warth, Arne  |d 910000  |d 912000  |e 910000PW132646145  |e 912000PW132646145  |k 0/910000/  |k 1/910000/912000/  |p 10 
999 |a KXP-PPN1580646743  |e 3024679359 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Lukas Bubendorf, Urania Dafni, Martin Schöbel, Stephen P. Finn, Verena Tischler, Aleksandra Sejda, Antonio Marchetti, Erik Thunnissen, Eric K. Verbeken, Arne Warth, Irene Sansano, Richard Cheney, Ernst Jan M. Speel, Daisuke Nonaka, Kim Monkhorst, Henrik Hager, Miguel Martorell, Spasenija Savic, Keith M. Kerr, Qiang Tan, Zoi Tsourti, Thomas R. Geiger, Roswitha Kammler, Katja Schulze, Ashis Das-Gupta, David Shames, Solange Peters, Rolf A. Stahel"]},"id":{"eki":["1580646743"],"doi":["10.1016/j.lungcan.2017.07.021"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"22 July 2017"}],"relHost":[{"title":[{"title":"Lung cancer","subtitle":"journal of the International Association for the Study of Lung Cancer","title_sort":"Lung cancer"}],"language":["eng"],"recId":"320649733","type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC results from the European Thoracic Oncology Platform (ETOP) Lungscape projectLung cancer","note":["Gesehen am 20.02.20"],"part":{"volume":"111","text":"111(2017), Seite 143-149","extent":"7","year":"2017","pages":"143-149"},"pubHistory":["1.1985 -"],"id":{"issn":["1872-8332"],"zdb":["2025812-4"],"eki":["320649733"]},"origin":[{"publisherPlace":"Amsterdam [u.a.]","dateIssuedDisp":"1985-","dateIssuedKey":"1985","publisher":"Elsevier"}],"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"7 S."}],"person":[{"given":"Lukas","family":"Bubendorf","role":"aut","roleDisplay":"VerfasserIn","display":"Bubendorf, Lukas"},{"roleDisplay":"VerfasserIn","display":"Warth, Arne","role":"aut","family":"Warth","given":"Arne"}],"title":[{"title":"Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC","subtitle":"results from the European Thoracic Oncology Platform (ETOP) Lungscape project","title_sort":"Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC"}],"language":["eng"],"recId":"1580646743","type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 04.09.2018"]} 
SRT |a BUBENDORFLPREVALENCE2220